New low-dose radiation therapy at Packard treats brain tumors while cutting brain damage risk

December 11, 2001

STANFORD, Calif., - Parents of children with brain tumors face an excruciating dilemma. Radiation necessary to kill life-threatening tumor cells can also damage normal brain tissue, resulting in permanent learning disabilities, memory problems and loss of motor control.

Physicians at Lucile Packard Children's Hospital at Stanford are now testing a new treatment that uses less radiation and more chemotherapy than conventional therapy. The study is part of a nationwide clinical trial aimed at preventing brain damage while treating medulloblastoma - the most common malignant brain tumor in children.

"It's double jeopardy for these families," said Paul Fisher, MD, assistant professor of neurology, pediatrics, and neurosurgery at Stanford University and Packard. "They have to deal not only with the fact that their child has cancer, but also that the treatment itself can hurt their brain." Because children's brains are still developing, long-term damage from radiation is more likely and more severe than that seen in adults receiving similar doses.

Packard is the only hospital west of Pennsylvania participating in the Phase II trial, which aims to enroll 50 children nationwide. About 25 children per year are diagnosed with medulloblastoma in Northern California, and about 20 of the trial's patients will be enrolled at Packard. Fisher, the trial's principal investigator at Packard, is about to enroll his third patient.

Brain tumors are the second most common pediatric cancer, and are the leading cause of disease-related death in children. Medulloblastomas account for 20 percent of childhood brain tumors - or 500 cases per year nationwide. The trial singles out medulloblastoma patients for treatment because the tumor is both common and curable; over 80 percent of average-risk children - those undergoing complete tumor removal with no evidence of tumor spread - are alive five years after their diagnosis. But the necessary treatment can also come at a devastating cost.

In the early 1990s, standard treatment for medulloblastoma called for 3600 cGy or rads (units of radiation), to the whole brain and spine, and even more to the cerebellum, where medulloblastomas are located. But even though this dose of radiation alone was often successful in eradicating the tumor, patients almost inevitably suffered severe neurological impairment as a result.

"Any child under seven who receives this dose of radiation to the head and spine is guaranteed to be in special education classes," said Fisher. Children are likely to suffer from memory problems and difficulties in visual motor processing, quantitative reasoning and understanding spatial relationships.

In an effort to protect the normal brain tissue from destruction, children are now normally treated with a dose of 2380 cGy, supplemented with several rounds of chemotherapy - a combination that gives equivalent survival rates as the higher dose of radiation alone. But the majority of these patients still come away with some degree of impairment, according to Fisher. "It's becoming clear now that even though this is a step in the right direction, these kids are still significantly affected," he said.

The current trial is designed to test whether 1800 cGy - combined with one extra round of chemotherapy - will be enough to conquer the tumor without damage to surrounding brain tissue. "The reason we're so excited is that children with leukemia who received this dose of radiation to their heads and spines to prevent metastases show that they maintain pretty close to normal neurological function," said Fisher. "And, seven out of 10 kids with medulloblastomas treated with 1800 cGy during a pilot study in the late 1980s are alive today. It would be so wonderful to be able to approach a family and say 'We're going to treat your child, and there are no strings attached,'" said Fisher.

The new treatment protocol calls for the patients to receive a total of 1800 cGy over the course of six weeks to the head and spine, with a boosted dose to the tumor itself. After a four-week break, patients begin nine cycles of chemotherapy, separated by six-week intervals. To volunteer for the trial, call pediatric neuro-oncology nurse practitioner Ruth Rosenblum at 650-723-7133.
In addition to Packard, the Children's Hospital of Philadelphia, New York University Hospitals, and Children's National Medical Center in Washington, are participating in the trial.

Lucile Salter Packard Children's Hospital at Stanford is a 240-bed hospital devoted entirely to the care of children and expectant mothers that is celebrating its tenth anniversary in 2001. Providing pediatric medical and surgical services associated with Stanford University Medical Center, Packard offers patients locally, regionally and nationally with the full range of health care programs and services - from preventive and routine care to the diagnosis and treatment of serious illness and injury. To learn more about Lucile Packard Children's Hospital, please visit our Web site at

Stanford University Medical Center

Related Chemotherapy Articles from Brightsurf:

Chemotherapy is used to treat less than 25% of people with localized sarcoma
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone.

Starved cancer cells became more sensitive to chemotherapy
By preventing sugar uptake, researchers succeeded in increasing the cancer cells' sensitivity to chemotherapeutic treatment.

Vitamin D could help mitigate chemotherapy side effects
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.

Less chemotherapy may have more benefit in rectal cancer
GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.

Male fertility after chemotherapy: New questions raised
Professor Delb├Ęs, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.

'Combo' nanoplatforms for chemotherapy
In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.

Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.

Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.

Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.

A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.

Read More: Chemotherapy News and Chemotherapy Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to